Janssen Pharmaceutical has filed a new drug application in Japan for its oral fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor erdafitinib for the treatment of certain patients… read more.
Merck Inc., known as MSD outside of the United States and Canada, announced that the Phase III AMBASSADOR (A031501) trial (KEYNOTE-123) evaluating Keytruda, Merck’s anti-PD-1 therapy, met one… read more.
Seagen Inc. and Astellas Pharma Inc. announced positive topline results from the Phase III EV-302 clinical trial (also known as KEYNOTE-A39) for Padcev (enfortumab vedotin-ejfv) in combination with… read more.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval of erdafitinib for… read more.
Frontline treatment with the combination of nivolumab (Opdivo) and cisplatin-based chemotherapy, followed by nivolumab monotherapy, led to a statistically significant improvement in progression-free survival (PFS) and overall survival… read more.
An on-going, worldwide shortage of bacillus Calmette-Guérin (BCG) means that many patients with a common and serious type of bladder cancer have limited access to this effective standard… read more.
Immunotherapy after surgery increased bladder cancer patients’ chance of staying cancer-free compared to patients who received a placebo, according to clinical trial results shared in a late-breaking oral… read more.
An epigenetics drug currently being used for the treatment of blood cancers and rare sarcomas can stop the growth of bladder cancer by activating the immune system, reports… read more.
Every year the European Association of Urology (EAU) hosts Urology Week, an international campaign for increasing awareness of urological conditions and treatment. This year, Urology Week (26-30 September… read more.
Bladder cancer is the 5th most common tumour in men and the 7-8th most common tumour women, according to Professor Arnulf Stenzl, Head of the Department of Urology in the… read more.
Current guidelines recommend a repeat TUR (re-TUR) for T1 bladder tumours but this carries risks and could be avoided if a good, complete TUR is done in the… read more.
According to the updated EAU guidelines long-term survival with trimodality bladder preserving treatment (TMT) could be as good as with radical cystectomy (RC), in selected patients. During the… read more.